Compare AUBN & CRDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AUBN | CRDL |
|---|---|---|
| Founded | 1907 | 2017 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 91.7M | 97.3M |
| IPO Year | 1995 | N/A |
| Metric | AUBN | CRDL |
|---|---|---|
| Price | $23.95 | $1.05 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $9.00 |
| AVG Volume (30 Days) | 2.7K | ★ 328.2K |
| Earning Date | 01-30-2026 | 11-13-2025 |
| Dividend Yield | ★ 4.44% | N/A |
| EPS Growth | ★ 754.96 | N/A |
| EPS | ★ 2.05 | N/A |
| Revenue | ★ $32,340,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $11.87 | ★ N/A |
| Revenue Growth | ★ 40.58 | N/A |
| 52 Week Low | $19.00 | $0.77 |
| 52 Week High | $29.00 | $1.59 |
| Indicator | AUBN | CRDL |
|---|---|---|
| Relative Strength Index (RSI) | 39.78 | 59.15 |
| Support Level | $23.70 | $0.94 |
| Resistance Level | $25.50 | $1.03 |
| Average True Range (ATR) | 0.65 | 0.05 |
| MACD | -0.28 | 0.00 |
| Stochastic Oscillator | 14.17 | 85.71 |
Auburn National Bancorp Inc operates as a bank holding company, which offers checking, savings, transaction deposit accounts and certificates of deposit, and is an active residential mortgage lender in its primary service area. The Bank's primary service area includes the cities of Auburn and Opelika, Alabama and nearby surrounding areas in East Alabama, predominantly in Lee County. The Bank also offers commercial, financial, agricultural, real estate construction and consumer loan products and other financial services. The Bank also provides automated teller machine (ATM) services in East Alabama and operates ATM machines. The Bank offers Visa Checkcards, which are debit cards. The Bank offers online banking, bill payment and other electronic banking services through its Internet website.
Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's main product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.